MET and lung cancer: High levels of ABCC8, ABCD1, BDNF, BIRC5, CDK4, CDKN2A, DLG4, GRIN2B, IGF1R, MET, MLST8, NFKB2, NGFR, NOTCH3, RASA4, SLC2A4, SLC3A2, SLC12A3, TP53, TP73, VEGFA, as well as low levels of ABL2, AKT2, CDK15, CFTR, DNMT3A, EFNA5, ERBB3, GLI3, ICAM1, JRK, KDM6A, LAMA3, LAMB1, LTBP1, MAP3K12, PFKFB3, RBBP4, SP4, TIMP3 were associated with poor survival in patients with lung cancer (Figure S1 and S2).